Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / November 22, 2023 / The Schall Law Firm,The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 1, 2023 and October 16, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 9, 2024.

GRAIL INVESTOR ALERT: The Schall Law Firm Encourages Investors in Illumina, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 1, 2023 and October 16, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 9, 2024.

IMPORTANT GRAIL INVESTOR ALERT: The Schall Law Firm Encourages Investors in Illumina, Inc. with Losses of $100,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #GRAIL--Illumina, Inc. (ILMN) Misled Investors Regarding Insider's Personal Motives for Acquiring GRAIL.

ILMN Stock News: Shareholders with Significant Losses Should Contact Robbins LLP for Information About Their Rights and Remedies Against Illumina, Inc.

RADNOR, Pa. , Nov. 18, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Illumina, Inc. ("Illumina") (NASDAQ: ILMN).

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Illumina, Inc.

If you purchased or acquired securities in Illumina between May 1, 2023 and October 16, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ILMN.

ILLUMINA SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Illumina To Contact Him Directly To Discuss Their Options

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Illumina, Inc. (“Illumina”) (NASDAQ: ILMN). The action charges Illumina with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a r.

ILMN Investor Announcement: Kessler Topaz Meltzer & Check, LLP Announces January 9, 2024 Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed Against Illumina, Inc. (ILMN)

LOS ANGELES, CA / ACCESSWIRE / November 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 1, 2023 and October 16, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 9, 2024.

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in Illumina, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Nov. 16, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Illumina, Inc. (NASDAQ: ILMN) between May 1, 2023 and October 16, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Illumina, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ILMN

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming January 9, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN) securities between May 1, 2023 and October 16, 2023, inclusive (the “Class Period”). Investors suffering losses on their Illumina investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal righ.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Illumina, Inc. (ILMN)

Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.

Illumina (ILMN) Launches Initiative on Pathogen Sequencing

LOS ANGELES, CA / ACCESSWIRE / November 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 1, 2023 and October 16, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 9, 2024.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Illumina, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired Illumina securities between May 1, 2023 and October 16, 2023, both dates inclusive (the “Class Period”). Investors.

ILLUMINA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Illumina, Inc. and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Illumina, Inc. (NASDAQ: ILMN) between May 1, 2023 and October 16, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2024. SO WHAT: If you purchased Illumina securities during the Class Period y.

EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Illumina, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ILMN

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #CarlIcahn--Illumina, Inc. (ILMN) Misled Investors Regarding Insider's Personal Motives for Acquiring GRAIL.

Illumina, Inc. (ILMN) Investor Notice: Robbins LLP Reminds Investors of Class Action Filed Against Illumina, Inc.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN) securities between May 1, 2023 and October 16, 2023, inclusive (the “Class Period”). If you suffered a loss on your Illumina investments or would like to inquire about potentially pursuing clai.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Illumina, Inc. (ILMN)

NEW YORK--(BUSINESS WIRE)---- $ILMN #classactionlawsuit--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN) securities during the period from May 1, 2023 through October 16, 2023 (the “Class Period”). Investors have until January 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. On August 10, 2023, Il.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Illumina, Inc. (ILMN) Investors

As shares of Illumina Inc. ILMN, +5.46% trade near 10-year lows, analysts are reining in expectations for the DNA-sequencing company.

As Illumina stock bounces off a 10-year low, analysts see no quick fix

Ligand Pharmaceuticals

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?

LGND or ILMN: Which Is the Better Value Stock Right Now?

Program aims to address key barriers to genomic sequencing in-country SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs). The program, developed with guidance from customers, funders, and market facilitators including the nonprofit FIND, will provide reduced pricing structures for eligible sequencing products from Illumina to qualified global health funding entities and address key international logistics and supply chain challenges.

Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN) securities between May 1, 2023 and October 16, 2023, inclusive (the “Class Period”). Illumina investors have until January 9, 2024 to file a lead plaintiff motion. Investors suffering losses on their Illumina investments are encouraged to contact the Law Offices of Howard G. Smith to d.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Illumina, Inc. (ILMN) Investors

Illumina (ILMN) shares fell to their lowest level in a decade after the genetic research equipment manufacturer missed revenue estimates and slashed its guidance as customers pulled back on spending.

Illumina Shares Hit a 10-Year Low as the Company's Customers Pull Back on Spending

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Kangas v. Illumina, Inc., et al., on behalf of persons and entities that purchased or otherwise acquired Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN) securities between May 1, 2023 and October 16, 2023, inclusive (the “Class Period”). Plaintiff pursues claims under Sections.

ILMN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc.

Hologic

Midday Movers: Hologic and Meta Platforms Gain, Illumina Sinks

Illumina stock crashed Friday after the DNA-reading behemoth slashed its outlook as pressures continue to build on life sciences companies.

DNA-Reading Giant Illumina Crashes As Macro Pressures Guidance — Again

Illumina Inc.'s stock ILMN, -13.91% fell 14% Friday to put it on track for its lowest close in 10 years, after the company after the maker of DNA-sequencing technology cut its full-year sales and profit guidance after missing revenue estimates for the third quarter. The stock was last quoted at $91.16.

News for Illumina Stock (ILMN)